New whipworm drug could beat standard treatment in one dose
NCT ID NCT07258173
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a single dose of emodepside to a single dose of albendazole (the usual treatment) in 100 adolescents and adults infected with a type of whipworm. The goal is to see which drug cures more infections and reduces egg counts. Participants provide stool samples before and 14-21 days after treatment to measure success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emodepside
What this could lead to
If successful, this could offer a new single-dose treatment for whipworm infections that is more effective than the current standard.
What could go wrong
This is a small Phase 2 trial with only 100 participants, so results may not apply broadly. The drug may not prove superior or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICHURIS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.